Kinfo
Precigen Inc. logo

Precigen Inc.

PGENNASDAQHealthcare·US · USD
$4.73
+0.26 (+5.82%)
Prices as of November 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap1.70B USD
Enterprise value1.66B USD
Trailing P/E40.64
Forward P/E-20.32
PEG ratio-0.24
Price / sales10.21
Price / book19.10
Profitability
Gross margin94.90%
Operating margin52.13%
Profit margin15.55%
Return on assets10.97%
Return on equity38.84%
Income (TTM)
Revenue156.94M USD
Gross profit116.93M USD
EBITDA38.08M USD
Net income24.41M USD
Diluted EPS$0.11
Rev. growth (YoY)2437.60%
Balance sheet
Total cash46.07M USD
Total debt98.61M USD
Debt / equity117.68
Current ratio5.58
Book value / share$0.23
Cash flow (TTM)
Operating cash flow-73.21M USD
Levered free cash flow-87.13M USD
Shares & price
Shares outstanding358.01M
Float194.88M
Held by institutions72.78%
Beta0.98
50-day MA$6.98
200-day MA$5.28
52-week high$8.98
52-week low$3.04
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-040.080.08+0.00%2026-08-04-0.010.05+600.00%2026-05-120.680.70+2.94%2026-03-25-0.08-0.01+87.50%
About Precigen Inc.

Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases. The company applies gene and cell therapy platforms to create targeted programs in immuno-oncology, autoimmune disorders, and infectious diseases. Its work centers on advancing innovative therapeutic candidates and related research tools that support discovery, preclinical development, and clinical development. Precigen also operates through business segments that include biopharmaceutical activities and specialized research-model services, giving it a broad presence across therapeutic development and life-science applications. Headquartered in Germantown, Maryland, Precigen serves as a clinical-stage innovator in the biotechnology sector, with an emphasis on translating proprietary technology platforms into potential treatments for patients with unmet medical needs.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Helen Sabzevari MPH, Ph.D.
Employees
160
Headquarters
Germantown, MD, United States

Frequently asked questions about Precigen Inc.